You are here

Article Text

Article menu
Download PDFPDF
Systematic review
Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis
  1. Fangfang Xiong1,
  2. Yunzhu Shen1,
  3. Ting Liu1,
  4. Yin Zhang1 and
  5. Xuehui Jiang2
  1. 1 Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
  2. 2 Department of Pharmacy, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China
  1. Correspondence to Xuehui Jiang; jxhsouth{at}163.com; Professor Yin Zhang; zyin1973{at}163.com

Abstract

Objective Osimertinib plays a crucial role in patients with non-small cell lung cancer (NSCLC). However, the haematological toxicities caused by osimertinib in such a population have not been well characterised. This analysis was performed to determine the incidence of osimertinib-related haematological toxicity in patients with NSCLC.

Method A literature search was conducted in PubMed, Embase, Cochrane Library and Web of Science. Eligible studies were included to describe the pooled incidences of anaemia, neutropenia and thrombocytopenia secondary to osimertinib in NSCLC patients.

Results 1288 patients from 10 studies were enrolled in this study. The overall incidences of osimertinib-related all-grade anaemia, neutropenia and thrombocytopenia in NSCLC patients were 21.1% (95% CI 10.9% to 33.3%), 14.6% (95% CI 5.9% to 26.1%) and 28.4% (95% CI 12.4% to 47.6%), respectively. In items of high-grade haematological toxicities, there were 0.5% (95% CI 0.1% to 1.1%) for anaemia, 2.0% (95% CI 0.3% to 4.6%) for neutropenia and 0.4% (95% CI 0% to 1.1%) for thrombocytopenia.

Conclusions There is non-negligible haematological toxicity associated with osimertinib, and it should be taken seriously.

  • Clinical assessment
  • Drug administration
  • Haematological disease
  • Palliative Care
  • Pharmacology

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

https://doi.org/10.1136/spcare-2024-005113

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    All data relevant to the study are included in the article or uploaded as supplementary information.

    View Full Text

    Footnotes

    • Contributors All authors contributed to the manuscript. FX designed this study and drafted the manuscript, and she is responsible for the overall content. The literature search and data analysis were performed by YS and FX. TL reviewed data for this study. YZ and XJ critically revised the manuscript. FX is the guarantor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.